Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
Trial ID or NCT#
NCT02216409
Status
NOT RECRUITING
Purpose
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
Official Title
A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies
Investigator(s)
Youn H Kim, MD
Dermatologic oncologist,
Cutaneous oncology specialist,
Dermatologist
The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)
Branimir I Sikic
Michael Khodadoust
Lymphoma specialist,
Cutaneous oncology specialist,
Hematologist,
Hematologist-Oncologist
Assistant Professor of Medicine (Oncology) and of Dermatology
Contact us to find out if this trial is right for you.
Contact
CCTO
1-650-498-7061
View on ClinicalTrials.gov
